J&J falls despite a beat-and-raise quarter. Why we're raising our price target anyways

Johnson & Johnson posted Q2 revenue of $25.31B (+6.6% YoY) vs. $25.05B consensus and adjusted EPS of $2.90 vs. $2.85 expected, but the stock is down ~2% intraday. Management raised full-year guidance, including adjusted EPS to $11.60–$11.75 (midpoint +8.2% YoY) and operational sales growth to 6.5%–7.1% (midpoint 7.3% YoY), with pre-tax operating margin expansion up to ~75 bps. The main offset was MedTech cardiovascular weakness (cardio sales $2.4B vs. $2.55B expected), though the broader MedTech segment still grew 3.6% operationally/4.5% reported.

Analysis

The market is still treating this like a single-quarter quality issue, but the more important signal is that the raise in full-year earnings and margin outlook implies the operating model is still compounding even with one MedTech pocket softening. That matters because JNJ is increasingly becoming a "re-rating through consistency" story: if pharma mid-single-digit growth is now being supplemented by double-digit growth in the newer immunology/neuroscience assets, the stock can hold a premium multiple even without big EPS surprises. The immediate dip looks more like positioning noise than a change in fundamentals.

The second-order dynamic is competitive. The oral IL-23 franchise gives JNJ a differentiated wedge versus ABBV’s injectable-heavy immunology mix, and the key question over the next 6-18 months is not whether the launch works, but how much it shifts share from incumbents in psoriasis and potentially GI. If prescription data keeps inflecting, ABBV faces incremental pressure in a market that has been more resilient than investors assume. On the other side, the cardiovascular/Abiomed weakness is a warning flag for procedure-sensitive medtech names: if HCA’s commentary proves broad, MDT is more exposed than JNJ because it lacks the pharma offset.

The contrarian view is that consensus may be underestimating how much of JNJ’s future upside comes from mix, not headline growth. The risk is that the current optimism around the new launches is premature: if early uptake normalizes or if Tremfya cannibalization appears in the next 1-2 quarters, the growth narrative loses some of its scarcity value. For the next few weeks, the cleanest tell is whether procedure-volume data stabilizes; if it doesn’t, the market may start to discount a slower MedTech path despite the pharma strength.

Key Decisions for Investors

• Use the post-earnings pullback to add JNJ on a 1-3 month horizon; the risk/reward favors owning a high-quality compounder where guidance revision, not the quarterly beat, is the real signal.
• Relative-value long JNJ / short MDT for 1-3 months: JNJ has pharma offset and launch optionality, while MDT is more directly levered to any broad procedure-volume softness; invalidate if medtech order trends re-accelerate.
• Do not fade ABBV aggressively yet, but put it on watch for 1-2 quarter prescription data: if oral IL-23 adoption in JNJ keeps outpacing expectations, ABBV’s immunology multiple deserves less scarcity premium.
• Buy JNJ on weakness rather than strength; if the stock cannot hold recent support after the market digests guidance, that would suggest the rotation trade is still dominant and the entry should be delayed.
• Set a trigger on MedTech/procedure data: if hospital volume commentary worsens again over the next earnings cycle, reduce exposure to MDT and other procedure-dependent device names; if it stabilizes, the JNJ cardio miss becomes a buyable noise event.